This repository is composed of two main folders: (1) “Exposure_fuzzy_scores” and (2) “Inter-scheme_mapping”. The first one contains an ipython notebook with a complete description of two earthquake building schemes: SARA and HAZUS in terms of faceted attributes contained in the GEM V.2.0 taxonomy. Both schemes have already been proposed for exposure modelling at the third administrative division “commune” in Chile in earlier works. They are inputs for the use of a Python script (contained in the second folder) to calculate an inter-scheme compatibility matrix, that uses SARA as the source and HAZUS as the target schemes. These models and data are supplement material to Gomez-Zapata et al. (2021).
This data publication is composed by two main folders:
(1) “Top-down_exposure_modelling_Lima” and
(2) “Vulnerability_models_Lima/”.
The first one contains a complete collection of data models used to represent the residential building portfolio of Lima and Callao (Peru) using a top-down approach (census-based desktop study). Therein, the reader can find a comprehensive description of the procedure of how the exposure models were constructed. This includes python scripts and postprocessed geodatasets to represent these building stock into predefined and separate classes for earthquake and tsunami physical vulnerabilities. The second folder contains sets of fragility functions for these building classes and the assumed economic consequence model. These models are suplement material of a submitted paper (Gomez-Zapata et al., 2021b). Please note it is an unpublished preprint version at the time of writing this document. The reader is strongly advised to look for the definitive version once (if so) it is accepted and published.
The overall objective of ERAP harm is to improve and complement existing knowledge and procedures for the environmental risk assessment (ERA) of human and veterinary pharmaceuticals. Based on EU regulatory frameworks on the ERA of pharmaceuticals and on the outcome of previous projects ERAP harm will address the following aspects: It will investigate previously unstudied major routes leading to exposure of the terrestrial and aquatic environment and subsequent fate of pharmaceuticals in surface water and sediment. Factors and processes affecting the behavior of pharmaceuticals in the environment will be studied on the laboratory, semi-field and fieldscale. A scenario-based exposure assessment system will be developed for predicting concentrations of pharmaceuticals in soils, surface waters and sediments and leaching to groundwater. It will be investigated if environmentally relevant concentrations of pharmaceuticals pose a risk to aquatic and terrestrial organisms. Pharmaceuticals and selected transformation products will be screened using in vitro and low complexity bioanalytical tests in order to provide a first hazard characterization and to target higher tier testing. Higher tier test methods will be improved and applied for detecting the effects of long-term, low-level exposure to pharmaceuticals on aquatic and terrestrial invertebrates and fish. It will be evaluated if information on pharmaco- and toxicodynamics in mammalian species can be used to predict effects of pharmaceuticals on environmental organisms. Moreover, the effects of antibiotics on microbial communities will be studied with a main focus on the spread of genetically encoded resistance. Based on the developed approaches recommendations will be provided on how to improve the ERA procedures for pharmaceuticals. A guidance document will be compiled that will be made available to regulators, industry and the scientific community.